Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

Autor: Thierry Facon, Gordon Cook, Saad Z. Usmani, Cyrille Hulin, Shaji Kumar, Torben Plesner, Cyrille Touzeau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Hartmut Goldschmidt, Hang Quach, Mohamad Mohty, Christopher P. Venner, Katja Weisel, Noopur Raje, Benjamin Hebraud, Karim Belhadj-Merzoug, Lotfi Benboubker, Olivier Decaux, Salomon Manier, Denis Caillot, Jon Ukropec, Huiling Pei, Rian Van Rampelbergh, Clarissa M. Uhlar, Rachel Kobos, Sonja Zweegman

Publikováno v: Leukemia
Leukemia, 2022, 36 (4), pp.1066-1077. ⟨10.1038/s41375-021-01488-8⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2022, ⟨10.1038/s41375-021-01488-8⟩
Leukemia, 36(4), 1066-1077. Nature Publishing Group
Facon, T, Cook, G, Usmani, S Z, Hulin, C, Kumar, S, Plesner, T, Touzeau, C, Bahlis, N J, Basu, S, Nahi, H, Goldschmidt, H, Quach, H, Mohty, M, Venner, C P, Weisel, K, Raje, N, Hebraud, B, Belhadj-Merzoug, K, Benboubker, L, Decaux, O, Manier, S, Caillot, D, Ukropec, J, Pei, H, van Rampelbergh, R, Uhlar, C M, Kobos, R & Zweegman, S 2022, ' Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA ', Leukemia, vol. 36, no. 4, pp. 1066-1077 . https://doi.org/10.1038/s41375-021-01488-8
Facon, T, Cook, G, Usmani, S Z, Hulin, C, Kumar, S, Plesner, T, Touzeau, C, Bahlis, N J, Basu, S, Nahi, H, Goldschmidt, H, Quach, H, Mohty, M, Venner, C P, Weisel, K, Raje, N, Hebraud, B, Belhadj-Merzoug, K, Benboubker, L, Decaux, O, Manier, S, Caillot, D, Ukropec, J, Pei, H, Van Rampelbergh, R, Uhlar, C M, Kobos, R & Zweegman, S 2022, ' Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA ', Leukemia, vol. 36, pp. 1066-1077 . https://doi.org/10.1038/s41375-021-01488-8

In the phase 3 MAIA study of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) versus lenalidomide/dexamethasone (Rd). We present a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bda7f76d64e69a6150c5a5ff816c8d03
https://doi.org/10.1038/s41375-021-01488-8

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Autor: Markus Munder, Hartmut Goldschmidt, Hans Salwender, Marc S. Raab, Jana Schlenzka, Martin Goerner, Marc-Andrea Baertsch, Martin Hoffmann, Peter Brossart, Dirk Hose, Anna Jauch, Jan Dürig, Stephan Fuhrmann, Steffen Luntz, Christina Kunz, Jens Hillengaß, Hans-Walter Lindemann, Kai Neben, Elias K. Mai, Henk M. Lokhorst, Thomas Hielscher, Ulrich Dührsen, Igor Wolfgang Blau, Hans Martin, Mathias Hänel, Pieter Sonneveld, Christof Scheid, Katja Weisel, Uta Bertsch, Helga Bernhard, Anja Seckinger, Britta Besemer

Publikováno v: Blood Cancer Journal
German-Speaking Myeloma Multicenter Group (GMMG) 2021, ' Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma ', Blood cancer journal, vol. 11, no. 1, 1 . https://doi.org/10.1038/s41408-020-00390-3
Blood Cancer Journal, 11(1):1. Nature Publishing Group
Blood cancer journal, 11(1):1. Nature Publishing Group
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-10 (2021)

Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dea567af161bdc07548c1280a7d542c
https://pure.eur.nl/en/publications/f4d5ebef-55fa-4986-a0fd-31a0368019df

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.